

SUPPLEMENTAL MATERIAL

Table S1. Baseline characteristics.

	N	ALL
Age	14980	70.0 (63.0 -- 76.0)
Sex:		
Male	14980	9649 (64.4%)
Female		5331 (35.6%)
Ethnicity:	14979	2167 (14.5%) [1]
Asian		
Black/African American		181 (1.2%)
White		12420 (82.9%)
Other		211 (1.4%)
Region:	14980	2395 (16.0%)
Asia/Pacific		
Europe		6044 (40.3%)
Latin America		2962 (19.8%)
North America		3579 (23.9%)
Weight	14937	82.0 (70.0 -- 95.5) [43]
Apixaban 2.5 mg at randomization	7498	325 (4.3%) [7482]
Creatinine	14971	1.0 (0.9 -- 1.2) [9]
Cystatin C	14884	1.0 (0.8 -- 1.2) [96]
Cockcroft-Gault	14928	74.1 (56.8 -- 95.3) [52]
MDRD	14970	66.5 (55.2 -- 78.6) [10]
CKD-EPI (Crea)	14971	68.5 (55.9 -- 82.0) [9]
CKD-EPI (CysC)	14884	74.2 (56.7 -- 96.0) [96]
CKD-EPI (Crea+CysC)	14874	72.6 (57.9 -- 87.4) [106]

Data presented as median (Q1-Q3) or frequency (percentage). Percentages computed by group. Brackets represents number of missing.

Table S2. Proportion of individuals with eGFR value <60 mL/min.

Cockcroft-Gault	MDRD	CKD-EPI (Crea)	CKD-EPI (Cystatin C)	CKD-EPI (Cystatin C and Crea)
29.5%	35.0%	32.6%	29.6%	28.1%

Figure S1. Illustration of the different eGFR methods in relation to sex, age, and biomarkers.

